Logo

Darmiyan Receives the US FDA’s Approval for BrainSee to Detect Alzheimer’s Dementia

Share this
Darmiyan

Darmiyan Receives the US FDA’s Approval for BrainSee to Detect Alzheimer’s Dementia

Shots:

  • The company received the US FDA’s approval for BrainSee, an automated software platform that generates an objective score predicting the likelihood of a patient progressing from Amnestic Mild Cognitive Impairment (aMCI) to Alzheimer’s Dementia within a span of 5yrs.
  • The software predicts the disease progression by combining standard clinical brain MRI with cognitive assessments incl. routine part & non-invasive workups of patients concerned with memory loss
  • Early screening through image processing & medical AI allows timely & personalized treatments for aMCI patients at high risk of progression to Alzheimer's dementia. Additionally, in 2021, Darmiyan received the BTD from the US FDA for BrainSee

Ref: PR Newswire Image: Darmiyan

Related News:- Eisai and Biogen’s Leqembi (Lecanemab) Receives the NMPA’s Approval for the Treatment of Alzheimer’s Disease

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions